Ghosh S, Bressler B, Petkau J, Thakkar R, Wang S, Skup M
Dig Dis Sci. 2019; 64(5):1142-1149.
PMID: 30659472
DOI: 10.1007/s10620-018-5419-3.
Wang H, Quan L, Liang J, Shi J, Qiu T, Zhang Y
Exp Ther Med. 2017; 14(6):5283-5288.
PMID: 29285054
PMC: 5740600.
DOI: 10.3892/etm.2017.5263.
Balasubramanian A, Wade S, Adler R, Lin C, Maricic M, OMalley C
Osteoporos Int. 2016; 27(11):3239-3249.
PMID: 27273113
DOI: 10.1007/s00198-016-3646-z.
Rajeev A
Int J Surg Case Rep. 2014; 5(5):246-8.
PMID: 24704729
PMC: 4008862.
DOI: 10.1016/j.ijscr.2014.03.001.
Nikkel L, Mohan S, Zhang A, McMahon D, Boutroy S, Dube G
Am J Transplant. 2011; 12(3):649-59.
PMID: 22151430
PMC: 4139036.
DOI: 10.1111/j.1600-6143.2011.03872.x.
Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma.
Dam T, Harrison S, Fink H, Ramsdell J, Barrett-Connor E
Osteoporos Int. 2009; 21(8):1341-9.
PMID: 19816753
PMC: 2895883.
DOI: 10.1007/s00198-009-1076-x.
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
Mauro M, Radovic V, Armstrong D
Can J Gastroenterol. 2007; 21(10):637-42.
PMID: 17948133
PMC: 2658130.
DOI: 10.1155/2007/216162.
Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.
Yeo H, Beck L, McDonald J, Zayzafoon M
Bone. 2007; 40(6):1502-16.
PMID: 17392048
PMC: 1974856.
DOI: 10.1016/j.bone.2007.02.017.
Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis.
Hurson C, Butler J, Keating D, Murray D, Sadlier D, OByrne J
BMC Musculoskelet Disord. 2007; 8:12.
PMID: 17295923
PMC: 1803771.
DOI: 10.1186/1471-2474-8-12.
Bone mineral density in Iranian patients with inflammatory bowel disease.
Zali M, Bahari A, Firouzi F, Ebrahimi Daryani N, Aghazadeh R, Emam M
Int J Colorectal Dis. 2006; 21(8):758-66.
PMID: 16463035
DOI: 10.1007/s00384-005-0084-3.
Longitudinal study of bone mineral density in patients with Crohn's disease.
de Jong D, Mannaerts L, van Rossum L, Corstens F, Naber A
Dig Dis Sci. 2003; 48(7):1355-9.
PMID: 12870795
DOI: 10.1023/a:1024171529000.
Pathogenesis of postmenopausal osteoporosis.
Raisz L
Rev Endocr Metab Disord. 2001; 2(1):5-12.
PMID: 11704980
DOI: 10.1023/a:1010074422268.
Corticosteroid-Induced osteoporosis: detection and management.
Adachi J, Papaioannou A
Drug Saf. 2001; 24(8):607-24.
PMID: 11480493
DOI: 10.2165/00002018-200124080-00005.
Comparative tolerability of treatments for inflammatory bowel disease.
Stein R, Hanauer S
Drug Saf. 2000; 23(5):429-48.
PMID: 11085348
DOI: 10.2165/00002018-200023050-00006.
A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C
Thorax. 1998; 53(5):351-6.
PMID: 9708225
PMC: 1745232.
DOI: 10.1136/thx.53.5.351.
Inflammatory bowel disease and predisposition to osteopenia.
Cowan F, Warner J, Dunstan F, Evans W, Gregory J, Jenkins H
Arch Dis Child. 1997; 76(4):325-9.
PMID: 9166024
PMC: 1717165.
DOI: 10.1136/adc.76.4.325.
Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.
Jahnsen J, Falch J, Aadland E, Mowinckel P
Gut. 1997; 40(3):313-9.
PMID: 9135518
PMC: 1027079.
DOI: 10.1136/gut.40.3.313.